Overall, although Trp53−/− mice exhibited clinical signs of over-inflammation following DSS treatment, by the time the adenocarcinomas were already present, we could not detect a strong inflammatory signal, aside from a slight increase in immune cell infiltration in Trp53−/− tumors. This evidence concerns the gene TP53 and adenocarcinoma.